NASDAQ · XERS
Xeris Biopharma Holdings, Inc.
Healthcare · Biotechnology
$10.07▼ 0.59% ($0.06)at close
As of 4:00 PM ET
Market cap
$1.74B
P/E
N/M
EPS (TTM)
-$0.10
Next earnings
Nov 5, 2026
Valuation
Revenue & margin DCF
Verdict: fairly priced. Price between Bear and Base.
The price needs 15.5% revenue growth a year for 10 years. Our scenarios assume 14.1–24.4%.
That's below its past 4-year pace of 55.8%.
Value per share
Base case
$14.64
Price used $10.07 is 31% below this
USD · TTM ending Jun 30, 2026 · Price Oct 6, 8:00 PM UTC
Revenue each value needs
Revenue today $335M. The price needs $1.4B by 2036. Base case: $2B. At its recent pace: $28.2B. Bear to Bull: $1.2B to $3B.
Revenue today $335M. The price needs $1.4B by 2036. Base case: $2B. At its recent pace: $28.2B. Bear to Bull: $1.2B to $3B.
Revenue in 2036
today $335M
−$591Mless than the Base case
Value per share · Base case
$14.64
Price $10.07
31% below this
- 10-yr revenue CAGR
- 19.6%
- Ending operating margin
- 13.9%
- Discount rate
- 10.4%
USD · TTM ending Jun 30, 2026 · Price Oct 6, 8:00 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 23.86% over the last year. Revenue grew 36.33% over the trailing twelve months. Operating margin moved from -3.99% to 10.91%. Free cash flow grew 430.06% over the trailing twelve months.
What the market seems to be pricing
The stock move broadly lines up with stronger business momentum, and the shares are still only around the 55th percentile of their historical P/S range.
What would invalidate this read
Operating margin is at 10.91%. Revenue grew 36.33% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.
Return analysis
Company profile
Xeris Biopharma Holdings, Inc. operates as a biopharmaceutical company, focusing on the development and commercialization of therapeutic solutions for individuals across the fields of endocrinology, neurology, and gastroenterology.
Market multiples
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
10
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 5, 2026
Q3 FY26 · EPS est $0.03 · Revenue est $101.68M
View
Institutional Sentiment
Xeris Biopharma Holdings, Inc. · XERS
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.